Guilford Licenses Inhibitor Class To Pfizer As Part Of Broad Deal

Guilford Pharmaceuticals Inc. is licensing an entire class of potential neurodegenerative disease drugs to Pfizer Inc. for $5 million up front in a deal that could become much more lucrative down the road. (BioWorld Today)